Detection of anti‐ EBV TCR CDR3s associated with better outcomes for EBV ‐positive, Ugandan cases of Burkitt lymphoma
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35212 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Rahul Jain und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Herpesvirus 4, Human, Epstein-Barr Virus Infections, Complementarity Determining Regions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Burkitt lymphoma (BL) has a tight association with Epstein–Barr virus (EBV), especially in sub‐Saharan Africa. While the relationship between BL and EBV is well documented, the relationship between the anti‐EBV adaptive immune response, particularly in sub‐Saharan African cases, and disease course, has not been substantially investigated. An analysis of T‐cell receptor (TCR) complementarity determining region‐3 (CDR3) sequences, reported here, from EBV‐positive, Ugandan BL tumor samples revealed a correlation between the presence of anti‐EBV CDR3s and improved overall survival probabilities. Furthermore, chemical complementarity assessments demonstrated higher complementarity for TCR CDR3s and EBV epitopes in the cases where there had been a detection of the anti‐EBV CDR3 AA sequence matches in the BL tumor samples. Overall, the results reported here raise the question of whether EBV targeted immunotherapy would lead to better BL outcomes?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
- Department of Pediatrics, Oregon Health and Science University Hospital, Portland, Oregon, USA.
- Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, Oregon, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
ORCID-Profile: George Blanck
Zitieren
APA
Jain, R., Huda, T. I., Paul, S., Chobrutskiy, A., Chobrutskiy, B. I., Baker, M. C., Goel, N., & Blanck, G. (2025). Detection of anti‐ EBV TCR CDR3s associated with better outcomes for EBV ‐positive, Ugandan cases of Burkitt lymphoma. International Journal of Cancer. https://doi.org/10.1002/ijc.35212
Vancouver
Jain R, Huda TI, Paul S, Chobrutskiy A, Chobrutskiy BI, Baker MC, et al. Detection of anti‐ EBV TCR CDR3s associated with better outcomes for EBV ‐positive, Ugandan cases of Burkitt lymphoma. International Journal of Cancer. 2025. doi:10.1002/ijc.35212
BibTeX
@article{Jain2025,
author = {Jain, Rahul and Huda, Taha I and Paul, Srijit and Chobrutskiy, Andrea and Chobrutskiy, Boris I and Baker, Madeline C and Goel, Nandini and Blanck, George},
title = {Detection of anti‐ EBV TCR CDR3s associated with better outcomes for EBV ‐positive, Ugandan cases of Burkitt lymphoma},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35212}
}
EUVIMED